Display options
Cite
Zhu JY, Lee JG, van de Leemput J, et al. Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment. Cell Biosci. 2021;11(1):59doi: 10.1186/s13578-021-00567-8.
Zhu, J. Y., Lee, J. G., van de Leemput, J., Lee, H., & Han, Z. (2021). Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment. Cell & bioscience, 11(1), 59. https://doi.org/10.1186/s13578-021-00567-8
Zhu, Jun-Yi, et al. "Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment." Cell & bioscience vol. 11,1 (2021): 59. doi: https://doi.org/10.1186/s13578-021-00567-8
Zhu JY, Lee JG, van de Leemput J, Lee H, Han Z. Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment. Cell Biosci. 2021 Mar 25;11(1):59. doi: 10.1186/s13578-021-00567-8. PMID: 33766136; PMCID: PMC7992514.
Copy Download .nbib Format: NLM
Share it on

Cell Biosci. 2021 Mar 25;11(1):59. doi: 10.1186/s13578-021-00567-8.

Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment.

Cell & bioscience

Jun-Yi Zhu, Jin-Gu Lee, Joyce van de Leemput, Hangnoh Lee, Zhe Han

Affiliations

  1. Center for Precision Disease Modeling, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  2. Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  3. Center for Precision Disease Modeling, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. [email protected].
  4. Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. [email protected].

PMID: 33766136 PMCID: PMC7992514 DOI: 10.1186/s13578-021-00567-8

Abstract

BACKGROUND: SARS-CoV-2 causes COVID-19 with a widely diverse disease profile that affects many different tissues. The mechanisms underlying its pathogenicity in host organisms remain unclear. Animal models for studying the pathogenicity of SARS-CoV-2 proteins are lacking.

METHODS: Using bioinformatic analysis, we found that 90% of the virus-host interactions involve human proteins conserved in Drosophila. Therefore, we generated a series of transgenic fly lines for individual SARS-CoV-2 genes, and used the Gal4-UAS system to express these viral genes in Drosophila to study their pathogenicity.

RESULTS: We found that the ubiquitous expression of Orf6, Nsp6 or Orf7a in Drosophila led to reduced viability and tissue defects, including reduced trachea branching as well as muscle deficits resulting in a "held-up" wing phenotype and poor climbing ability. Furthermore, muscles in these flies showed dramatically reduced mitochondria. Since Orf6 was found to interact with nucleopore proteins XPO1, we tested Selinexor, a drug that inhibits XPO1, and found that it could attenuate the Orf6-induced lethality and tissue-specific phenotypes observed in flies.

CONCLUSIONS: Our study established Drosophila as a model for studying the function of SARS-CoV2 genes, identified Orf6 as a highly pathogenic protein in various tissues, and demonstrated the potential of Selinexor for inhibiting Orf6 toxicity using an in vivo animal model system.

References

  1. Science. 2014 Mar 21;343(6177):1243727 - PubMed
  2. J Virol. 2007 Oct;81(20):11054-68 - PubMed
  3. Dis Model Mech. 2020 Apr 30;13(4): - PubMed
  4. Animal Model Exp Med. 2020 Mar 30;3(1):93-97 - PubMed
  5. EMBO J. 2002 Dec 16;21(24):6801-10 - PubMed
  6. Cell. 2020 Aug 6;182(3):744-753.e4 - PubMed
  7. J Gen Virol. 2005 Jul;86(Pt 7):1921-1930 - PubMed
  8. Protein J. 2020 Jun;39(3):198-216 - PubMed
  9. Genome Res. 2003 Nov;13(11):2498-504 - PubMed
  10. J Virol. 2007 Jan;81(2):548-57 - PubMed
  11. Virus Res. 2006 Dec;122(1-2):20-7 - PubMed
  12. Nature. 2020 Oct;586(7830):560-566 - PubMed
  13. J Virol. 2007 Jun;81(12):6346-55 - PubMed
  14. Dev Cell. 2019 Dec 16;51(6):713-729.e6 - PubMed
  15. Biochem Biophys Res Commun. 2020 Feb 17;: - PubMed
  16. Drugs. 2019 Sep;79(13):1485-1494 - PubMed
  17. Nat Methods. 2012 Jul;9(7):671-5 - PubMed
  18. Emerg Microbes Infect. 2020 Dec;9(1):1418-1428 - PubMed
  19. Oncotarget. 2016 Nov 29;7(48):78883-78895 - PubMed
  20. J Cell Sci. 2005 May 1;118(Pt 9):1851-9 - PubMed
  21. Emerg Microbes Infect. 2017 Mar 22;6(3):e13 - PubMed
  22. Med (N Y). 2021 Jan 15;2(1):99-112.e7 - PubMed
  23. Cell Host Microbe. 2018 Jul 11;24(1):57-68.e3 - PubMed
  24. Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515 - PubMed
  25. mBio. 2013 Aug 13;4(4): - PubMed
  26. BMC Bioinformatics. 2011 Aug 31;12:357 - PubMed
  27. Virology. 2012 Feb 5;423(1):1-5 - PubMed
  28. Science. 2020 May 29;368(6494):1012-1015 - PubMed
  29. Nature. 2020 Jul;583(7818):830-833 - PubMed
  30. J Exp Med. 2020 Dec 7;217(12): - PubMed
  31. Trends Pharmacol Sci. 2020 Aug;41(8):513-517 - PubMed
  32. Virus Res. 2020 Sep;286:198074 - PubMed
  33. J Cell Sci. 2001 Aug;114(Pt 15):2787-94 - PubMed
  34. Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28344-28354 - PubMed
  35. Int J Biol Macromol. 2020 Nov 15;163:1-8 - PubMed
  36. Nature. 2020 Jul;583(7816):459-468 - PubMed
  37. J Virol. 2006 Jan;80(2):785-93 - PubMed
  38. J Virol. 2007 Sep;81(18):9812-24 - PubMed
  39. Virol J. 2005 Aug 17;2:66 - PubMed

Publication Types